EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture

Antony Johansen, Opinder Sahota, Frances Dockery, Alison J Black, Alasdair M J MacLullich iD, M Kassim Javaid, Emer Ahern, Celia L Gregson

Age and Ageing · 01.09.2023 · 52 (9)

DOI: 10.1093/ageing/afad172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 30.09.2023. Verfasst von Antony Johansen und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Wales and College of Medicine, Cardiff University, Cardiff CF14 4XW, UK. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Hip Fractures, Osteoporotic Fractures, Zoledronic Acid. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Versus Arthritis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently in the UK and Ireland, after a hip fracture most patients do not receive bone protection medication to reduce the risk of refracture. Yet randomised controlled trial data specifically examining patients with hip fracture have shown that intravenous zoledronate reduces refracture risk by a third. Despite this evidence, use of intravenous zoledronate is highly variable following a hip fracture; many hospitals are providing this treatment, whilst most are currently not. A range of clinical uncertainties, doubts over the evidence base and practical concerns are cited as reasons. This paper discusses these concerns and provides guidance from expert consensus, aiming to assist orthogeriatricians, pharmacists and health services managers establish local protocols to deliver this highly clinically and cost-effective treatment to patients before they leave hospital, in order to reduce costly re-fractures in this frail population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsHip FracturesOsteoporotic FracturesZoledronic AcidHumansIreland

Stichwörter der Autor:innen

hip fractureolder peopleosteoporosissecondary preventionzoledronate

Substanzen

Bone Density Conservation AgentsZoledronic Acid

Autor:innen und Institutionen

  • University Hospital of Wales and College of Medicine, Cardiff University, Cardiff CF14 4XW, UK.
  • Falls and Fragility Fracture Audit Programme, Royal College of Physicians, London NW1 4LE, UK.
  • Department of Health Care of Older People, Nottingham University Hospital, Nottingham NG7 2UH, UK.
  • Beaumont Hospital, Dublin 9, Ireland.
  • NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK.
  • Ageing and Health Research Group, University of Edinburgh, Edinburgh EH9 3EG, UK.

ORCID-Profile: Alasdair M J MacLullich

Förderung

  • Versus Arthritis

Zitieren

APA

Johansen, A., Sahota, O., Dockery, F., Black, A. J., MacLullich, A. M. J., Javaid, M. K., Ahern, E., & Gregson, C. L. (2023). Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture. Age and Ageing, 52(9). https://doi.org/10.1093/ageing/afad172

Vancouver

Johansen A, Sahota O, Dockery F, Black AJ, MacLullich AMJ, Javaid MK, et al. Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture. Age and Ageing. 2023;52(9). doi:10.1093/ageing/afad172

BibTeX
@article{Johansen2023,
  author = {Johansen, Antony and Sahota, Opinder and Dockery, Frances and Black, Alison J and MacLullich, Alasdair M J and Javaid, M Kassim and Ahern, Emer and Gregson, Celia L},
  title = {Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture},
  journal = {Age and Ageing},
  year = {2023},
  volume = {52},
  number = {9},
  doi = {10.1093/ageing/afad172}
}
Kostenlos starten →